Jerry Younger

6.6k citations

60 papers · 3.9k indexed · 1 hit paper · h-index 29

Oncology top 1%
Pulmonary and Respiratory Medicine top 1%
Cancer Research top 2%
Radiology, Nuclear Medicine and Imaging top 2%
Molecular Biology

Co-authors: Eric P. Winer Harold J. Burstein Irene Kuter Rebecca Gelman Craig A. Bunnell Susan M. Domchek Lyndsay N. Harris Leroy M. Parker
Topics: Breast Cancer Treatment Studies (16 papers)Cancer Treatment and Pharmacology (15 papers)Brain Metastases and Treatment (11 papers)
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: New England Journal of Medicine Journal of Clinical Oncology JNCI Journal of the National Cancer Institute
Partner nations: United States Norway Switzerland

In The Last Decade

Jerry Younger

60 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

2003 554 citations Johanna C. Bendell, Susan M. Domchek et al. Cancer profile →

Peers

Countries citing papers authored by Jerry Younger

Since Specialization

Citations

This map shows the geographic impact of Jerry Younger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerry Younger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerry Younger more than expected).

Fields of papers citing papers by Jerry Younger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerry Younger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerry Younger. The network helps show where Jerry Younger may publish in the future.

Co-authorship network of co-authors of Jerry Younger

This figure shows the co-authorship network connecting the top 25 collaborators of Jerry Younger. A scholar is included among the top collaborators of Jerry Younger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerry Younger. Jerry Younger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer 2021 ·Clinical Cancer Research ·Neelima Vidula,Andrzej Niemierko,(unknown),(unknown),Jochen K. Lennerz,A. John Iafrate,Seth A. Wander,Laura M. Spring,Dejan Juric,Steven J. Isakoff,Jerry Younger,Beverly Moy,Leif W. Ellisen,Aditya Bardia	12
2	Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases 2020 ·Breast Cancer Research ·José Pablo Leone,Kyrre E. Emblem,(unknown),Rebecca Gelman,Bryan P. Schneider,Rachel A. Freedman,Jerry Younger,Marco C. Pinho,A. Gregory Sorensen,Elizabeth R. Gerstner,Gordon J. Harris,Ian E. Krop,Daniel Morganstern,Jessica Sohl,Jiani Hu,(unknown),Eric P. Winer,Nancy U. Lin	36
3	FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer 2019 ·Clinical Cancer Research ·Joshua Z. Drago,Luigi Formisano,Dejan Juric,Andrzej Niemierko,Alberto Servetto,Seth A. Wander,Laura M. Spring,Neelima Vidula,Jerry Younger,Jeffrey Peppercorn,(unknown),(unknown),Dennis C. Sgroi,Steven J. Isakoff,Beverly Moy,Leif W. Ellisen,A. John Iafrate,Carlos L. Arteaga,Aditya Bardia	47
4	A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases 2013 ·Breast Cancer Research and Treatment ·Nancy U. Lin,Rachel A. Freedman,Naren Ramakrishna,Jerry Younger,Anna Maria Storniolo,Jennifer R. Bellon,Steven E. Come,Rebecca Gelman,Gordon J. Harris,M. Henderson,Shannon M. MacDonald,Anand Mahadevan,(unknown),Jennifer A. Ligibel,Erica L. Mayer,Beverly Moy,April F. Eichler,Eric P. Winer	48
5	Nonviolent Communication Training and Empathy in Male Parolees 2011 ·Journal of Correctional Health Care ·Elizabeth Marlow,Adeline Nyamathi,(unknown),(unknown),(unknown),Jerry Younger	42
6	Faith and Mental Health in an Oncology Population 2011 ·Journal of Religion and Health ·Janice Bell Meisenhelder,(unknown),Jerry Younger,(unknown)	11
7	The non-breast-cancer death rate among breast cancer patients 2010 ·Breast Cancer Research and Treatment ·(unknown),Barbara L. Smith,Jerry Younger,James Michaelson	11
8	The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death 2009 ·Cancer ·L. Leon Chen,Matthew Nolan,Melvin J. Silverstein,Martín C. Mihm,Arthur J. Sober,Kenneth K. Tanabe,Barbara L. Smith,Jerry Younger,James Michaelson	50
9	Survival in patients with brain metastases from breast cancer 2008 ·Cancer ·April F. Eichler,Irene Kuter,Paula D. Ryan,Lidia Schapira,Jerry Younger,John W. Henson	130
10	Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide 2008 ·Supportive Care in Cancer ·Paul J. Hesketh,Jerry Younger,Pedro Sanz-Altamira,Melissa A. Hayden,(unknown),Brian C. Trainor,(unknown),(unknown),Konstantinos Arnaoutakis,(unknown)	15
11	Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel 2008 ·Cancer Treatment Reviews ·Minetta C. Liu,George D. Demetri,Donald A. Berry,Larry Norton,Gloria Broadwater,Nicholas J. Robert,David B. Duggan,Daniel F. Hayes,I. Craig Henderson,Alan P. Lyss,Judith O. Hopkins,Peter A. Kaufman,P. Kelly Marcom,Jerry Younger,Nancy U. Lin,Katherine H. R. Tkaczuk,Eric P. Winer,Clifford A. Hudis	11
12	Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomabreakdown → 2003 ·Cancer ·Johanna C. Bendell,Susan M. Domchek,Harold J. Burstein,Lyndsay N. Harris,Jerry Younger,Irene Kuter,Craig A. Bunnell,Montserrat Rué,Rebecca Gelman,Eric P. Winer	554
13	Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study 2002 ·Journal of Clinical Oncology ·Harold J. Burstein,Lyndsay N. Harris,Rebecca Gelman,Susan C. Lester,Raquel Nunes,Carolyn M. Kaelin,Leroy M. Parker,Leif W. Ellisen,Irene Kuter,Michele A. Gadd,Roger Christian,Patricia Kennedy,Virginia F. Borges,Craig A. Bunnell,Jerry Younger,Barbara L. Smith,Eric P. Winer	221
14	Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. 2001 ·PubMed ·Daniel F. Hayes,Hideko Yamauchi,Gloria Broadwater,Constance Cirrincione,(unknown),Donald A. Berry,Jerry Younger,Lawrence Panasci,Frederick Millard,David B. Duggan,Larry Norton,I. Craig Henderson	75
15	2074 Increased risk of radiation pneumonitis in breast cancer patients treated by concomitant taxol and radiation therapy 1999 ·International Journal of Radiation OncologyBiologyPhysics ·Alphonse G. Taghian,Sherif Assaad,Irene Kuter,Jerry Younger,Robin Schoenthaler,Brian G. Czito,Manon Roche,Simon N. Powell	7
16	Alternating chemotherapy regimens for patients with metastatic breast cancer. A pilot study based on tumor marker kinetics 1995 ·Cancer ·David T. Kiang,B. J. Kennedy,Jerry Younger,(unknown),Albert Schilling,Ann H. Korzun,(unknown),William Wood,(unknown)	5
17	N-nitroso compounds, nitrite and pH in human fasting gastric juice 1994 ·Carcinogenesis ·(unknown),Jean-Louis Paul,M Gaudric,J Guerre,Jerry Younger,Ohvanesse G. Ekindjian	6
18	Management of Lithium in Patients With Cancer 1993 ·Psychosomatics ·Donna Greenberg,Jerry Younger,Sheldon Kaufman	12
19	Percutaneous balloon pericardial window for patients with malignant pericardial effusion and tamponade 1991 ·Catheterization and Cardiovascular Diagnosis ·Igor F. Palacios,(unknown),Andrew A. Ziskind,Jerry Younger,P C Block	71
20	A Feasibility Study of Intensive CAF as Outpatient Adjuvant Therapy for Stage II Breast Cancer in a Cooperative Group: CALGB 8443 1990 ·Cancer Investigation ·Daniel R. Budman,Ann H. Korzun,Joseph Aisner,Jerry Younger,R T Silver,Mary E. Costanza,(unknown),W. C. Wood	7

About Jerry Younger

Jerry Younger is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 60 papers that have together received 3.9k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (16 papers), Cancer Treatment and Pharmacology (15 papers) and Brain Metastases and Treatment (11 papers). The work is most often cited by research in Oncology (2.7k citations), Cancer Research (802 citations) and Pulmonary and Respiratory Medicine (1.5k citations). Jerry Younger has collaborated with scholars based in United States, Norway and Switzerland. Frequent co-authors include Eric P. Winer, Harold J. Burstein, Irene Kuter, Rebecca Gelman, Craig A. Bunnell, Susan M. Domchek, Lyndsay N. Harris, Leroy M. Parker, Montserrat Rué and Johanna C. Bendell. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact